CN101365806B - 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途 - Google Patents

用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途 Download PDF

Info

Publication number
CN101365806B
CN101365806B CN200680052220.2A CN200680052220A CN101365806B CN 101365806 B CN101365806 B CN 101365806B CN 200680052220 A CN200680052220 A CN 200680052220A CN 101365806 B CN101365806 B CN 101365806B
Authority
CN
China
Prior art keywords
gene
treatment
patient
purposes
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200680052220.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN101365806A (zh
Inventor
S·克努森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alaretti Therapeutics Europe Pte Ltd
Alaretti Treatment Co
Oncology Risk Product Development Co
Allarity Therapeutics Europe ApS
Original Assignee
Medical Prognosis Institute AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Prognosis Institute AS filed Critical Medical Prognosis Institute AS
Publication of CN101365806A publication Critical patent/CN101365806A/zh
Application granted granted Critical
Publication of CN101365806B publication Critical patent/CN101365806B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN200680052220.2A 2005-12-01 2006-12-01 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途 Active CN101365806B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200501696 2005-12-01
DKPA200501696 2005-12-01
PCT/IB2006/004048 WO2007072225A2 (fr) 2005-12-01 2006-12-01 Méthodes et appareils pour identifier des biomarqueurs de réponse à un traitement et leur utilisation pour prédire l'efficacité d’un traitement

Publications (2)

Publication Number Publication Date
CN101365806A CN101365806A (zh) 2009-02-11
CN101365806B true CN101365806B (zh) 2016-11-16

Family

ID=38189039

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200680052220.2A Active CN101365806B (zh) 2005-12-01 2006-12-01 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途

Country Status (5)

Country Link
EP (1) EP1960551A2 (fr)
JP (3) JP5984324B2 (fr)
CN (1) CN101365806B (fr)
CA (1) CA2631236C (fr)
WO (1) WO2007072225A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110331200A (zh) * 2019-06-28 2019-10-15 中山大学附属第六医院 Cd47检测试剂在制备结直肠癌对抗egfr单抗耐药诊断剂方面的应用

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008286408A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for EGFR inhibitor treatment
PL2198042T3 (pl) 2007-09-17 2017-05-31 Mdxhealth Sa Nowe markery do wykrywania raka pęcherza moczowego
WO2010024374A1 (fr) * 2008-08-29 2010-03-04 学校法人北里研究所 Méthode de détection des effets sur des médicaments des inhibiteurs de méthylation de l'adn
GB0816867D0 (en) * 2008-09-15 2008-10-22 Glaxosmithkline Biolog Sa Method
KR20120088555A (ko) 2009-05-11 2012-08-08 버그 바이오시스템즈, 엘엘씨 환경대사적 전환인자, 다차원 세포내 분자 또는 환경적 영향인자를 사용한 대사적 장애의 진단 방법
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
TW201136604A (en) * 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
JP6083735B2 (ja) * 2009-12-31 2017-02-22 カッパーアールエヌエー,インコーポレイテッド インスリン受容体基質2(irs2)および転写因子3(tfe3)に対する天然アンチセンス転写物の阻害によるインスリン受容体基質2(irs2)関連疾患の治療
NZ600268A (en) 2010-01-11 2014-08-29 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CA2800557A1 (fr) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methodes et dispositifs permettant de predire l'efficacite d'un traitement
KR101869413B1 (ko) 2010-06-14 2018-06-20 리케라 바이오메드 에스에이 S100a4 항체들 및 이들의 치료 용도
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
EP2913405B1 (fr) 2010-07-27 2016-11-09 Genomic Health, Inc. Procédé d'utilisation de l'expression génique pour déterminer le pronostic du cancer de la prostate
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
CA3176977A1 (fr) 2010-09-10 2012-03-15 Epizyme, Inc. Inhibiteurs de l'ezh2 humaine, et leurs procedes d'utilisation
CN102408478A (zh) * 2010-09-21 2012-04-11 复旦大学 一种人少突神经胶质瘤标志物map2蛋白及其用途
JP2014502606A (ja) * 2010-12-15 2014-02-03 メディミューン,エルエルシー 黒色腫の処置
DK2666015T3 (en) * 2011-01-21 2017-03-27 Basilea Pharmaceutica Ag USE OF STATHMIN AS A BIOMARKETER FOR PHARMACEUTICAL RESPONSE TO FURAZANOBENZIMIDAZOLES
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
KR101439856B1 (ko) * 2011-06-02 2014-09-17 한국생명공학연구원 항-atic 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
CN104024851A (zh) * 2011-11-28 2014-09-03 加拿大国家研究委员会 针对癌症的紫杉醇反应标志物
US8725426B2 (en) 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
US9663825B2 (en) 2012-04-19 2017-05-30 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
CA2871995A1 (fr) * 2012-05-04 2013-11-07 Novartis Ag Biomarqueurs pour therapie par inhibiteur de iap
DK2872646T3 (en) * 2012-07-12 2017-12-04 Université Paris Descartes PROCEDURES FOR PREDICTING SURVIVAL TIME AND TREATMENT RESPONSE OF A PATIENT, SUFFERING A FAST CANCER WITH A SIGNATURE OF AT LEAST 7 GENES
PE20150887A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
CN105338973A (zh) 2013-04-08 2016-02-17 博格有限责任公司 使用辅酶q10联合疗法治疗癌症
AU2014274135B2 (en) 2013-05-30 2020-04-09 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
SG11201601583TA (en) 2013-09-04 2016-04-28 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
JP2017508469A (ja) * 2014-03-11 2017-03-30 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 癌悪性度、予後及び治療に対する反応性の決定
CN103923212A (zh) * 2014-03-31 2014-07-16 天津市应世博科技发展有限公司 Ehd2抗体及其在制备乳腺癌免疫组化检测试剂中的应用
CN104945496B (zh) * 2014-03-31 2019-05-03 天津市应世博科技发展有限公司 一种多肽及其在制备与纯化对ehd2特异的抗体中的应用
FR3025028A1 (fr) * 2014-08-22 2016-02-26 Acobiom Procede pour determiner le pronostic de survie d'un patient atteint d'un cancer du pancreas
WO2016046640A2 (fr) 2014-09-26 2016-03-31 Medical Prognosis Institute A/S Procédés de prédiction de la réactivité à un médicament
KR101674874B1 (ko) * 2014-10-21 2016-11-22 한국원자력의학원 항암제 내성 예측용 바이오마커로서의 icam-3 및 이의 용도
CN105777901B (zh) * 2014-12-25 2019-07-09 中国科学院上海生命科学研究院 一种抗qki-5单克隆抗体及其制备与应用
WO2016121715A1 (fr) * 2015-01-26 2016-08-04 国立大学法人名古屋大学 Procédé de fourniture d'informations pour évaluer le pronostic d'un patient atteint de cancer du poumon, procédé de prédiction de pronostic de patient atteint de cancer du poumon, standard interne, anticorps, dispositif pour prédire le pronostic d'un patient atteint de cancer du poumon, programme pour dispositif de prédiction de pronostic, et support d'enregistrement
GB201503371D0 (en) * 2015-02-27 2015-04-15 Mission Therapeutics Ltd Methods of screening and treatment
CN104749381B (zh) * 2015-03-30 2017-03-15 石河子大学 组装抑制蛋白pfn2在制备食管癌诊断试剂中的用途
CN105132415A (zh) * 2015-08-19 2015-12-09 天津市康婷生物工程有限公司 锰超氧化物歧化酶sod2的体外分子检测方法及引物
CN105132429A (zh) * 2015-10-10 2015-12-09 华东理工大学 靶向人KPNB1基因的siRNA及其应用
CN105424935B (zh) * 2015-11-09 2017-08-25 吉林大学 多聚谷氨酰化dnajc7的新应用
CN105506107A (zh) * 2015-12-30 2016-04-20 杭州艾迪康医学检验中心有限公司 检测dock2基因多态热点突变情况的引物和方法
CA3234176A1 (fr) * 2016-02-05 2017-08-10 Antje Margret Wengner Composes, compositions et methodes pour la stratification de patients cancereux et le traitement d'un cancer
CN105787297A (zh) * 2016-03-12 2016-07-20 云南圣清环境监测科技有限公司 一种微生物修复系统活性评价的方法
WO2017167788A1 (fr) * 2016-03-29 2017-10-05 Universite Paris Diderot Paris 7 Compositions comprenant des vésicules extracellulaires sécrétées de cellules exprimant nfatc4 utiles pour le traitement du cancer
WO2018039490A1 (fr) * 2016-08-24 2018-03-01 Genomedx Biosciences, Inc. Utilisation de signatures génomiques en vue d'une prédiction de la réactivité de patients atteints d'un cancer de la prostate à une radiothérapie postopératoire
JP6779517B2 (ja) * 2016-09-02 2020-11-04 国立大学法人 鹿児島大学 抗癌剤の感受性及び癌の予後に対する診断マーカー
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
CN106399582B (zh) * 2016-12-20 2019-12-24 上海杏园瑞民生物工程有限公司 一种检测与结直肠癌靶向用药西妥昔单抗治疗敏感性相关基因的多态性的试剂盒及其应用
AU2017258901A1 (en) * 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
AU2018202878A1 (en) 2017-05-16 2018-12-06 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
CN107266567B (zh) * 2017-06-05 2021-06-04 高新 Lcrmp4单克隆抗体及其制备方法与应用
CN109207589A (zh) * 2017-07-05 2019-01-15 安徽普元生物科技股份有限公司 一步法实时荧光定量逆转录聚合酶链反应检测人细胞角蛋白7的试剂盒
WO2019018451A2 (fr) * 2017-07-17 2019-01-24 The Regents Of The University Of Colorado Compositions et méthodes de prévention et de traitement d'effets de proximité induits par rayonnement provoqués par un rayonnement ou une radiothérapie
CN109387630A (zh) * 2017-08-14 2019-02-26 杭州源昶医药科技有限公司 用于预测吉西他滨药物敏感性的生物标记物及其用途
CN109470854B (zh) * 2017-09-08 2022-02-11 广州市丹蓝生物科技有限公司 肺癌诊断用蛋白芯片及试剂盒
JP7357921B2 (ja) * 2017-09-29 2023-10-10 国立大学法人九州大学 びまん性大細胞型b細胞リンパ腫患者における化学療法に対する治療効果を予測するための方法及びキット
EP3792363B1 (fr) * 2018-01-23 2024-06-26 Excellen Medical Technology Co., Ltd. Méthode et kit pour identifier l'état d'un cancer du poumon
US20220324835A1 (en) * 2018-01-26 2022-10-13 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
CN108796077B (zh) * 2018-05-30 2021-11-09 朱运峰 在cfDNA中检测胞嘧啶脱氨酶及相关分子基因修饰差异的引物对组及试剂盒
WO2020047604A1 (fr) * 2018-09-06 2020-03-12 The Council Of The Queensland Institute Of Medical Research Biomarqueurs pour la cancérothérapie
BR122023024103A2 (pt) 2018-10-15 2024-02-20 Nurix Therapeutics, Inc. Compostos bifuncionais para degradação de btk por meio da via de proteossoma de ubiquitina, composição farmacêutica compreendendo os mesmos, e seus usos
US20220002815A1 (en) * 2018-11-04 2022-01-06 Pfs Genomics, Inc. Methods and genomic classifiers for prognosis of breast cancer and predicting benefit from adjuvant radiotherapy
CN109402260A (zh) * 2018-11-28 2019-03-01 陕西中医药大学 Rims3基因作为肝癌检测的生物标志物及应用
US20220081727A1 (en) * 2019-01-17 2022-03-17 Geninus Inc. Biomarker for predicting response to anticancer agent and use thereof
IL287049B2 (en) 2019-04-09 2025-01-01 Nurix Therapeutics Inc Trisubstituted piperidine compounds for inhibiting CBL-B, and use of a CBL-B inhibitor in combination with a cancer vaccine and/or oncolytic virus
WO2020236654A1 (fr) 2019-05-17 2020-11-26 Nurix Therapeutics, Inc. Composés cyano-cyclobutyle pour l'inhibition de cbl-b et leurs utilisations
KR20220026581A (ko) 2019-06-26 2022-03-04 누릭스 테라퓨틱스 인코포레이티드 Cbl-b 억제를 위한 치환된 벤질-트리아졸 화합물, 및 이의 추가의 용도
WO2021050490A1 (fr) * 2019-09-13 2021-03-18 The Trustees Of Columbia University In The City Of New York Procédés d'amélioration de la radiothérapie au moyen d'inducteurs de ferroptose en tant que radiosensibilisateurs
EP4034141A1 (fr) 2019-09-24 2022-08-03 Nurix Therapeutics, Inc. Inhibiteurs de cbl et compositions pour l'expansion de cellules immunitaires
US11820781B2 (en) 2019-12-04 2023-11-21 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
CN110951876A (zh) * 2019-12-17 2020-04-03 蔡清清 一种淋巴瘤预后试剂盒
CN111321228B (zh) * 2020-03-13 2021-03-05 中国医学科学院肿瘤医院 抗pd-1治疗敏感性相关基因及其应用
KR102363980B1 (ko) * 2020-04-13 2022-02-15 전남대학교산학협력단 전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법
JP2024514836A (ja) 2021-04-08 2024-04-03 ニューリックス セラピューティクス,インコーポレイテッド Cbl-b阻害化合物との組み合わせ療法
TW202307203A (zh) * 2021-07-15 2023-02-16 日商富士軟片股份有限公司 特定細胞的品質管理方法及製造特定細胞之方法
CN113593700B (zh) * 2021-08-06 2024-02-27 江苏师范大学 分析肺癌进展的方法、装置、设备、介质及程序产品
CN113493840A (zh) * 2021-09-07 2021-10-12 北京泱深生物信息技术有限公司 子宫内膜癌诊断用标志物及其衍生产品和应用
GB202117299D0 (en) * 2021-11-30 2022-01-12 Queens Univ Of Belfast Method of prognosis
KR102701566B1 (ko) * 2021-12-29 2024-09-04 인하대학교 산학협력단 Ifi44의 발현 또는 활성 억제제를 유효성분으로 포함하는 방사선 민감성 증진용 약학 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072722A1 (en) * 2002-10-10 2004-04-15 Kornblith Paul L. Methods for assessing efficacy of chemotherapeutic agents
JP2002531066A (ja) * 1998-11-05 2002-09-24 パーカー ヒューズ インスティテュート イカロス(ikaros)アイソフォームおよび突然変異体
WO2000034788A1 (fr) * 1998-12-08 2000-06-15 Board Of Regents, The University Of Texas System Procedes de detection du cancer du sein resistant aux anti-oestrogenes
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US7324926B2 (en) * 1999-04-09 2008-01-29 Whitehead Institute For Biomedical Research Methods for predicting chemosensitivity or chemoresistance
JP2006506945A (ja) * 2002-03-28 2006-03-02 メディカル・カレッジ・オブ・オハイオ 遺伝子発現プロフィールを使用する非小細胞肺癌の診断および処置のための方法および組成物
JP2004043446A (ja) * 2002-05-15 2004-02-12 Schering Ag ヒストンデアセチラーゼ抑制剤及びその使用
CN102342938B (zh) * 2002-05-17 2014-08-20 细胞基因公司 用于治疗和控制实体瘤的方法及组合物
JP2007501608A (ja) * 2003-08-08 2007-02-01 株式会社 キャンバス 抗癌治療の効力を推定するための感受性試験
WO2005047534A2 (fr) * 2003-10-28 2005-05-26 Bayer Healthcare Ag Procedes et compositions de prediction de reponse de la neoplasie maligne a un traitement
US20050147978A1 (en) * 2003-12-30 2005-07-07 Jose Remacle Method for quantitative determination of multi-drug resistance in tumors
ES2394799T3 (es) * 2003-12-31 2013-02-05 The Penn State Research Foundation Métodos para predecir y superar la resistencia a quimioterapia en cáncer de ovario
US20070270488A1 (en) * 2004-03-12 2007-11-22 The Queen's University Of Belfast Treatment and Assays
CN1972703A (zh) * 2004-03-30 2007-05-30 丹麦皇家兽医和农业学院 通过阻断和检测蛋白酶抑制剂改进癌症的治疗和癌症治疗效率的预测
ES2550614T3 (es) * 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110331200A (zh) * 2019-06-28 2019-10-15 中山大学附属第六医院 Cd47检测试剂在制备结直肠癌对抗egfr单抗耐药诊断剂方面的应用

Also Published As

Publication number Publication date
WO2007072225A2 (fr) 2007-06-28
JP2016026496A (ja) 2016-02-18
CA2631236C (fr) 2019-10-29
EP1960551A2 (fr) 2008-08-27
WO2007072225A3 (fr) 2008-07-10
JP2009523011A (ja) 2009-06-18
JP2014147386A (ja) 2014-08-21
CA2631236A1 (fr) 2007-06-28
CN101365806A (zh) 2009-02-11
WO2007072225A8 (fr) 2008-11-06
JP5984324B2 (ja) 2016-09-06

Similar Documents

Publication Publication Date Title
CN101365806B (zh) 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
US8445198B2 (en) Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2008138578A2 (fr) Procédés, coffrets et dispositifs pour identifier des biomarqueurs de réponse à un traitement et utilisation de ceux-ci pour prédire l'efficacité du traitement
US10570457B2 (en) Methods for predicting drug responsiveness
US8877445B2 (en) Methods for identification of tumor phenotype and treatment
EP2563936B1 (fr) Méthodes et dispositifs permettant de prédire l'efficacité d'un traitement
US11866787B2 (en) Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
US20150301055A1 (en) Circulating biomarkers for disease
CN103492590A (zh) 循环生物标志物
EP4428157A2 (fr) Utilisation de l'expression génique spécifique de cellules immunitaires pour le pronostic du cancer de la prostate et la prédiction de la réactivité à une radiothérapie
WO2009029266A2 (fr) Outil de diagnostic pour diagnostiquer des lésions de la thyroïde bénignes versus malignes
US10900089B2 (en) Methods for predicting drug responsiveness in cancer patients
US20210164056A1 (en) Use of metastases-specific signatures for treatment of cancer
Ma et al. Polymorphisms of key chemokine genes and survival of non-small cell lung cancer in Chinese
US20240318258A1 (en) Biomarkers for breast cancer detection
US20100055686A1 (en) Methods for diagnosis of pediatric common acute lymphoblastic leukemia by determining the level of gene expression
US20240344132A1 (en) Method of Treating Liver Cancer, Predicting Response to Treatment, and Predicting Adverse Effects During the Treatment Thereof
US20240254565A1 (en) Unique cancer associated fibroblast subsets predict response to immunotherapy
US12104210B2 (en) Blood RNA biomarkers of coronary artery disease
US20200340995A1 (en) A New Approach For Universal Monitoring Of Minimal Residual Disease In Acute Myeloid Leukemia
WO2023102193A1 (fr) Méthodes et compositions associées à un panel de gènes inflammatoires
Pizzini et al. An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer
AU2014200767A1 (en) Methods for identifying, diagnosing, and predicting survival of lymphomas

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1128496

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1128496

Country of ref document: HK

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Dane Hess Holm

Patentee after: Alaretti Treatment Co.

Address before: Dane Hess Holm

Patentee before: Oncology Venture APS

Address after: Dane Hess Holm

Patentee after: Oncology Venture APS

Address before: Dane Hess Holm

Patentee before: MEDICAL PROGNOSIS INSTITUTE A/S

Address after: Dane Hess Holm

Patentee after: Alaretti Therapeutics Europe Pte. Ltd.

Address before: Dane Hess Holm

Patentee before: Oncology Risk Product Development Co.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20221129

Address after: Dane Hess Holm

Patentee after: Oncology Risk Product Development Co.

Address before: Dane Hess Holm

Patentee before: Alaretti Treatment Co.